Abstract
Due to the rapid approval of some of the newer therapies for COVID-19 infection, there are several pharmacologic aspects of these therapies that are not fully known, including drug-drug interactions. Transplant recipients face notable risks in relation to these interactions. This article outlines complications arising from the concurrent administration of nirmatrelvir/ritonavir and tacrolimus in a patient with history of combined kidney and liver transplantation. Additionally, it highlights the effective utilization of phenytoin as an inducer to correct the supratherapeutic levels of tacrolimus.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
